What is the role of teriparatide in the treatment of osteogenesis imperfecta (OI)?

Updated: Feb 24, 2020
  • Author: Manoj Ramachandran, MBBS, MRCS, FRCS; Chief Editor: Harris Gellman, MD  more...
  • Print
Answer

Teriparatide is a recombinant human form of parathyroid hormone that increases the number and activity of osteoblasts. It has been approved by the US Food and Drug Administration (FDA) for use in osteoporosis, but because of the potential risk of osteosarcoma induction (as seen in preclinical studies in rats), it has not been approved by the FDA for use in children and adolescents. The potential use of teriparatide for the treatment of OI remains to be defined.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!